Cholesterol is a significant risk factor for non-alcoholic steatohepatitis

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue 11, 2015, Pages 1343-1346

  Walenbergh, Sofie M A ^a   Shiri Sverdlov, Ronit ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

cholesterol; inflammation; lipids; liver; non alcoholic steatohepatitis

Indexed keywords

CHOLESTEROL; EZETIMIBE; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL; AUTACOID; BIOLOGICAL MARKER;

CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; HEPATITIS; HUMAN; INFLAMMATION; LIPID STORAGE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATION; PATHOGENESIS; REVIEW; RISK FACTOR; ANIMAL; BLOOD; COMPLICATION; DYSLIPIDEMIAS; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BIOMARKERS; CHOLESTEROL; DYSLIPIDEMIAS; FATTY ACIDS, NONESTERIFIED; HEPATITIS; HUMANS; INFLAMMATION MEDIATORS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RISK FACTORS; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 84947127221     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.1092382     Document Type: Review

References (33)

1. Walenbergh SM, Koek GH, Bieghs V, Shiri-Sverdlov R. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatol 2013; 58 (4): 801-10
2. Hendrikx T, Walenbergh SM, Hofker MH, Shiri-Sverdlov R. Lysosomal cholesterol accumulation: driver on the road to inflammation during atherosclerosis and non-alcoholic steatohepatitis. Obesity Rev 2014; 15 (5): 424-33
3. Puri P, Wiest MM, Cheung O, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009; 50 (6): 1827-38
4. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46 (4): 1081-90
5. Younossi ZM, Gorreta F, Ong JP, et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Intern 2005; 25 (4): 760-71
6. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterol 1998; 114 (4): 842-5
7. Wouters K, van Gorp PJ, Bieghs V, et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatol 2008; 48 (2): 474-86
8. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45 (6): 1366-74
9. Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol 2013; 218 (3): R25-36
10. Moylan CA, Pang H, Dellinger A, et al. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatol 2014; 59 (2): 471-82
11. Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 2014; 15 (5): 8591-638
12. Argo CK, Patrie JT, Lackner C, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol 2015; 62 (1): 190-7
13. Tanaka N, Sano K, Horiuchi A, et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008; 42 (4): 413-18
14. Leamy AK, Egnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Progress Lipid Res 2013; 52 (1): 165-74
15. Romestaing C, Piquet MA, Bedu E, et al. Long term highly saturated fat diet does not induce NASH in Wistar rats. Nutrition & Metab 2007; 4: 4
16. Mari M, Caballero F, Colell A, et al. Mitochondrial free cholesterol loading sensitizes to TNF-and Fas-mediated steatohepatitis. Cell Metab 2006; 4 (3): 185-98
17. Subramanian S, Han CY, Chiba T, et al. Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese LDL receptor-deficient mice. Arteriosclerosis Thromb Vasc Biol 2008; 28 (4): 685-91
18. Min HK, Kapoor A, Fuchs M, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012; 15 (5): 665-74
19. Caballero F, Fernandez A, De Lacy AM, et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepat 2009; 50 (4): 789-96
20. Ioannou GN, Haigh WG, Thorning D, Savard C. Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. J Lipid Res 2013; 54 (5): 1326-34
21. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol 2015; 15 (2): 104-16
22. Chung S, Cuffe H, Marshall SM, et al. Dietary cholesterol promotes adipocyte hypertrophy and adipose tissue inflammation in visceral, but not in subcutaneous, fat in monkeys. Arteriosclerosis Thromb Vasc Biol 2014; 34 (9): 1880-7
23. Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest 2014; 124 (10): 4204-11
24. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatol 2010; 52 (5): 1836-46
25. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99 (8): 1497-502
26. Griffin EE, Ullery JC, Cox BE, Jerome WG. Aggregated LDL and lipid dispersions induce lysosomal cholesteryl ester accumulation in macrophage foam cells. J Lipid Res 2005; 46 (10): 2052-60
27. Tomita K, Teratani T, Suzuki T, et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 2014; 59 (1): 154-69
28. Baratta F, Pastori D, Del Ben M, et al. Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease. EBioMed 2015; 2 (7): 750-4
29. Davidson MH, Voogt J, Luchoomun J, et al. Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. Atherosclerosis 2013; 230 (2): 322-9
30. Pastori D, Polimeni L, Baratta F, et al. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Digestive and liver Dis 2015; 47 (1): 4-11
31. Bieghs V, van Gorp PJ, Walenbergh SM, et al. Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology 2012; 56 (3): 894-903
32. Bieghs V, Hendrikx T, van Gorp PJ, et al. The cholesterol derivative 27-hydroxycholesterol reduces steatohepatitis in mice. Gastroenterol 2013; 144 (1): 167-78
33. Plat J, Hendrikx T, Bieghs V, et al. Protective role of plant sterol and stanol esters in liver inflammation: insights from mice and humans. PLoS One 2014; 9 (10): e110758